Association of early antibiotic de-escalation with length of stay in patients with myeloid neoplasms and neutropenic fever.

Authors

null

Xiao Wang

Hospital of the University of Pennsylvania, Philadelphia, PA

Xiao Wang, Swarn V Arya, Mary Angela Decena, Julia Powers, Daniel J Landsburg, Rebecca Hirsh, Matthew J Ziegler

Organizations

Hospital of the University of Pennsylvania, Philadelphia, PA

Research Funding

No funding received
None.

Background: Neutropenic fever is a common complication in patients with myeloid neoplasms. While patients typically receive intravenous (IV) antibiotics until neutrophil recovery, a growing body of literature shows the safety of de-escalation prior to this endpoint. The impact of this early de-escalation on health care utilization remains unclear. Methods: We conducted a retrospective analysis of hospitalized myeloid neoplasm patients at our institution with neutropenic fever, assessing the impact of IV antibiotic de-escalation prior to neutrophil recovery on length of stay (LOS). Manual chart review was performed on this cohort to assess clinical outcomes. Multivariable linear regression was performed, adjusting for age, diagnosis, Charlson Comorbidity Index, intensity of chemotherapy received, positive bacterial culture result, last hospital day with fever, and last hospital day with neutropenia. Results: Patient characteristics are shown in Table 1. Most de-escalation patients (67.7%) were discharged within 72 hours of stopping IV antibiotics. After adjusting for the above variables, early antibiotic de-escalation was associated with lower LOS of 2.7 days (95% confidence interval [CI] 2.0–3.3 days, p< 0.001), an effect that appeared most pronounced in the high very risk chemotherapy group (3.6 day reduction, 95% CI 2.5–4.6 days, p = 0.007). Review of clinical outcomes of de-escalation patients showed 5 potentially preventable recurrent or worsening fever or infectious incidents. Conclusions: Early de-escalation of IV antibiotics was associated with a statistically and clinically significant reduction in LOS, with very few clinical complications. To our knowledge, our study is the first to demonstrate a significant reduction in length of stay, an important hospital quality metric. Further prospective data is needed to confirm this relationship.

CharacteristicOverall, N = 4771De-Escalation, N = 1351No De-Escalation, N = 3421p-value2
Age63 (53, 69)62 (49, 70)63 (53, 69)0.6
Disease0.4
acute myeloid leukemia448 (94%)125 (93%)323 (94%)
myelodysplastic syndrome29 (6.1%)10 (7.4%)19 (5.6%)
Chemotherapy3<0.001
very high305 (64%)57 (42%)248 (73%)
high45 (9.4%)27 (20%)18 (5.3%)
moderate43 (9.0%)15 (11%)28 (8.2%)
other26 (5.5%)9 (6.7%)17 (5.0%)
none58 (12%)27 (20%)31 (9.1%)
Charlson Comorbidity Index>0.9
09 (1.9%)4 (3.0%)5 (1.5%)
1235 (49%)66 (49%)169 (49%)
2151 (32%)41 (30%)110 (32%)
355 (12%)17 (13%)38 (11%)
4+27 (5.6%)7 (5.2%)20 (5.8%)
Bacterial infection4152 (32%)33 (24%)119 (35%)0.029
Last hospital day with fever16 (11, 24)15 (7, 25)17 (12, 23)0.033
Last hospital day with neutropenia24 (17, 31)27 (14, 37)24 (18, 29)0.2

1 Median (IQR); n (%)

2 Wilcoxon rank sum test; Pearson’s Chi-squared test; Fisher’s exact test

3 Categorized by degree of immunosuppression

4 Defined as positive microbiologic culture at any time during hospitalization

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Quality Care Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship

Sub Track

Quality Improvement Research and Implementation Science

Citation

JCO Oncol Pract 19, 2023 (suppl 11; abstr 425)

DOI

10.1200/OP.2023.19.11_suppl.425

Abstract #

425

Poster Bd #

J7

Abstract Disclosures

Similar Abstracts

First Author: Shamali Poojary

Abstract

2020 Genitourinary Cancers Symposium

Transperineal prostate biopsies without antibiotic prophylaxis: Safety evaluation of the first 65 patients.

First Author: Tobias Kohl

First Author: Benjamin Lichtbroun